Mineralys Therapeutics Inc. Common Stock (MLYS)
Stock · NASDAQ · Health Care
$20.3as of 10/16/2026
Price chart
Active signals
Resistance level
$26.61
Industry
Biotechnology: Pharmaceutical Preparations
MLYS Signal Track Record
How signals performed across all stocks →What MLYS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | -1.2% | 48% | September 18, 2026 |
| Bollinger Band Breakout | 18 | -10.6% | 39% | September 2, 2026 |
| Bollinger Band Breakdown | 14 | +4.4% | 64% | September 29, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +0.4% | 50% | September 10, 2026 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since November 27, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 76
- Website
- mineralystx.com/
Fundamentals
- 1-day range
- $20.41$22.82
- Market cap
- $2.23B
- P/E (trailing)
- —
- P/E (forward)
- -8.40
- EPS (trailing)
- $-4.24
- Dividend yield
- —
- Beta
- 0.61
- Avg. volume
- 1.05M
52-week range
$21.46$47.65
Next earnings: November 10, 2026 · EPS estimate $-0.54confirmed
Forecasts
9 analyst ratings
Buy 88%
Hold 13%
Sell 0%
1-year price forecast
High
$56
+175.9%
Median
$52
+156.2%
Low
$29
+42.9%
Mineralys Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026Yahoo · 10/1/2026
- Mineralys Therapeutics To Present Five Abstracts At American Heart Association Hypertension Scientific Sessions 2026,Benzinga · 10/1/2026
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/29/2026
- Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat DataYahoo · 9/28/2026
- Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic ForumYahoo · 9/24/2026
- Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026Yahoo · 9/23/2026
- Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026Benzinga · 9/23/2026
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/21/2026
Insider Activity
Insider Actions →Acquired
265.3K
Disposed
206.8K
- Jon Congleton · September 30, 2026 · Sale75.0K @ $25.46
- Brian Taylor Slingsby · September 22, 2026 · Sale104.3K @ $28.81
- Eric Warren · September 21, 2026 · Option Exercise7.4K @ $13.24
- Eric Warren · September 21, 2026 · Sale7.4K @ $28.12
- Daphne Karydas · September 15, 2026 · Sale3.0K @ $28.58
- Daphne Karydas · September 15, 2026 · Option Exercise3.0K @ $12.02
- Eric Warren · August 21, 2026 · Option Exercise7.4K @ $13.24
- Eric Warren · August 21, 2026 · Sale7.4K @ $25.98
- James J. Ferguson III · August 10, 2026 · Grant135.0K
- James J. Ferguson III · August 10, 2026 · Grant102.4K
- David Malcom Rodman · August 10, 2026 · Option Exercise2.2K @ $16
- David Malcom Rodman · August 10, 2026 · Sale2.2K @ $27.09
- Eric Warren · July 21, 2026 · Option Exercise7.4K @ $13.24
- Eric Warren · July 21, 2026 · Sale7.4K @ $26.87
- David Malcom Rodman · July 17, 2026 · Option Exercise416 @ $15.44
Institutional Ownership
March 31, 2026
- Total shares held
- 96.46M
- Total value held
- $2.56B
- Institutional holders
- 210
Top holders this quarter
- Unknown7.90M
- Unknown7.69M
- Unknown5.87M
- Unknown4.86M
- Unknown4.48M
- Unknown3.36M
- Unknown3.27M
- Unknown2.94M
- Unknown2.77M
- Unknown2.45M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.